Lazard Asset Management
ONC

Lazard Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Lazard Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7M Buy
90,348
+27,431
+44% +$8.08M 0.04% 304
2026
Q1 		$18.7M Buy
62,917
+14,696
+30% +$4.76M 0.03% 332
2025
Q4 		$14.7M Buy
48,221
+6,841
+17% +$2.24M 0.02% 366
2025
Q3 		$14.1M Buy
41,380
+17,688
+75% +$5.37M 0.02% 365
2025
Q2 		$5.74M Buy
23,692
+11,197
+90% +$2.75M 0.01% 693
2025
Q1 		$3.4M Buy
+12,495
New +$2.92M 0.01% 806
2021
Q3 		– Sell
-3,055
Closed -$1.05M – 2316
2021
Q2 		$1.05M Buy
+3,055
New +$1.01M ﹤0.01% 943
2021
Q1 		– Sell
-689
Closed -$178K – 2058
2020
Q4 		$178K Hold
689
– – ﹤0.01% 1113
2020
Q3 		$197K Buy
+689
New +$162K ﹤0.01% 967
2018
Q1 		– Sell
-1,580
Closed -$154K – 1134
2017
Q4 		$154K Buy
+1,580
New +$145K ﹤0.01% 894

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lazard Asset Management's ONC Position: Q2 2026 in Review

Lazard Asset Management increased its BeOne Medicines Ltd (ONC) stake by 44% in Q2 2026, buying an estimated $8.08M and bringing the position to 90,348 shares worth $25.7M. The position accounts for 0.04% of the portfolio, ranked #304.

Lazard Asset Management first reported a position in ONC in Q4 2017 and has held it in 10 quarters since. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Lazard Asset Management held 90,348 shares of BeOne Medicines Ltd worth $25.7M as of Q2 2026.
  • Lazard Asset Management bought 27,431 BeOne Medicines Ltd shares in Q2 2026, an estimated $8.08M.
  • BeOne Medicines Ltd made up 0.04% of Lazard Asset Management's portfolio in Q2 2026, its #304 holding.
  • Lazard Asset Management first reported a position in BeOne Medicines Ltd in Q4 2017 and has held it in 10 quarters since.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.